About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site   |  How to Help!

Patients Against Lymphoma

 

Locate Trials by type of agent 

Last update: 07/25/2014


Agents of special interest based on recent encouraging clinical reports

bullet
ABT-199  (activating apoptosis) Find trials
bullet
Adcetris ®  SGN-35 / brentuximab vedotin  (antibody-drug conjugate: anti-cd30 + antitubulin)  Find trials
bullet
Belinostat PXD101 (epigenetic - recent approval) Find trials
bullet
Cd19 CAR T-cell therapy (adoptive immunotherapy) Find trials 
bullet
GA-101 (Obinutuzumab), next generation cd20 antibody  Find trials
bullet
Lenalidomide (immune modulation and direct activity)  Find trials
bullet
Ibrutinib (all - recent approval for CLL; inhibiting b-cell receptor pathway) Find trials
bullet
Ibrutinib for lymphoma only  Find Trials
bullet
Idelalisib GS-1101 formerly CAL101 (inhibiting b-cell receptor pathway)  Find trials
bullet
PD1/L antibodies (activates immune system - mmune checkpoints)  Find trials 
bullet
Vidaza ®  5-Azacytidine (epigenetic - activating or shutting off genes) Find trials 


What's New

bullet
Testing MLN9708 (Ixazomib, GATA-3 inhibitor) for Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas http://1.usa.gov/1iEFBYz

MLN9708 is an investigational, potent, reversible, and specific 20S proteasome inhibitor (next generation Velcade with better anticipated safety profile)

Goal is to determine the extent to which MLN9708 inhibits GATA-3 (Trans-acting T-cell-specific transcription factor) expression, which is associated with poor prognosis, and whether GATA-3 expression represents a novel predictive biomarker for MLN9708 sensitivity.


Background - early results: “MLN9708, a Novel, Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma: Results http://bit.ly/1pdqkBR 
bullet
PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients” http://1.usa.gov/1lBvVC8

Rationale: ASH Paper: - PI3K-δ Inhibitor TGR-1202 With Brentuximab Vedotin Synergistically Induces G2/M Phase Arrest and Cell Death In Hodgkin Cell Lines http://bit.ly/1qppOEu
bullet
ASCO Post: “Novel Agents Show Activity in relapsed Non-Hodgkin Lymphoma”
including CRs http://bit.ly/1dSn1gv
Promising reports in this article - impressive outcomes - particularly for single agents in relapse setting.
Agent

BOLD names are
FDA approved agents


 
B or T cell 
 
Target
of Drug
 
Approved
Indication
or note
 
Queries

Locate
Studies on
ClinicalTrials.gov
 

Counting
 Clicks
as of
3/7/13


4,651
Find
Clinical Reports
on Agent

Google
Scholar
 

Monoclonal antibodies (Mab)
  See also Immune mediated

Monoclonal antibodies (MAbs) are similar to antibodies produced by the body in response to infection.  MAbs bind to specific receptor expressed on the tumor and some normal cells.

 

 
Agent name or class
Click to search for
 mechanism of action
 

  Target  

Find Trials


 
Count

6/23/14
 
Clinical Reports

 
MEDI-551 (humanized antibody) 
 

B cd19 - Find trials  59 Reports    >

 
cd-19-based antibodies
 

B cd19 - Find trials 19 Reports   >

 
 
Arzerra
® (Ofatumumab)
 

B cd20 - Find trials 199 Reports   >

 
Rituxan ® (Rituximab / Mabthera)
 

B cd20 - Find trials
 
82 Reports   >

 
GA-101 (Obinutuzumab)
 

B cd20 - Find trials
 
430 Reports   >

 
Ublituximab
 

B cd20 - Find trials
>
24 Reports  

 
Veltuzumab / Immu-106 / Ha20
 

B cd20 - Find trials
 
13 Reports   >

 
Epratuzumab
 

B cd22 - Find trials
 
89 Reports   >

 
Lumiliximab
 

B cd23 - Find trials
 
43 Reports   >

 
SGN-30
 

B / T cd30 - Find trials
 
56 Reports   >

 
TRU-016
 

B cd37 - Find trials
 
104 Reports   >

 
Zanolimumab
 

T cd4 - Find trials
 
63 Reports   >

 
Campath ® (alemtuzumab)
 

B cd52 - Find trials
 
39 Reports   >

 
MDX-1411
 

B / T cd70 - Find trials

 
55 Reports    >

 
Milatuzumab / hLL1
 

B cd74 - Find trials
 
51 Reports   >

 
IMMU-114 (anti-HLA-DR)
 

  HLA-DR - Find trials
 
13 Reports   >

 
Mogamulizumab (Mogo)
(KW-0761; AMG-761)
 

T CCR4 - Find trials
 
63 Reports   >

PAL

Bispecific antibodies

Binding two receptors expressed on tumor cells and/or other immune cells

 


Agent name or class

  Target  

Find Trials

Count

6/23/14

 
Reports

  
DT2219ARL

Bi
specific antibody+immunotoxin
 

B cd19 cd22 Initial
count:
 
72 >
 
 Find trials
 >
 

combined count:
 

90

 

Reports


 
Blinatumomab / MT103 / BiTe)
 

B cd3 cd19 -  
 
Find trials
>
 
111 Reports

antibody-drug conjugates

Antibodies that deliver toxins to extracellular (CD) targets on tumor cells

Reports by class


Agent name or class

  Target  

Find Trials

 
Count

6/23/14
 
Reports

  
SGN-CD19A
anti-CD19 + toxin
 

B cd19 -  
Find trials
>
 
15 Reports

 
 
SAR3419
anti-CD19 + maytansinoi
  

B cd19 -
Find trials
>
 
114 Reports

 
DT2219ARL
anti-CD19 & 22 antibody + immunotoxin
 

B cd19 cd22 - Find trials
>
 
108 Reports

 
Inotuzumab Ozogamicin
anti-CD22 + calicheamicin

 

B cd22 - Find trials
>
 
214 Reports

 
DCDT2980S
anti-CD22, conjugated to MMAE
 

B cd22 - Find trials
>
 
22 Reports

 
LMB-2 immunotoxin
anti-CD25 antibody + immunotoxin
 

B cd25 - Find trials
>
 
30 Reports

 
Adcetris ® 
(SGN-35 / brentuximab vedotin)
anti-cd30 + antitubulin
 

B/T cd30 HL / ALCL Find trials
>
222 Reports

Technical - PK / dosing

Radio-immunotherapy

Antibodies delivering radiation to tumor cells

 
Agent or class

  Target  

Find Trials

 
Count

6/23/14
 
Reports

Radioimmunotherapy  

     

 
Find trials
>
 

3 Reports

 
Betalutin 
(Lu-tetraxetan-tetulomab)
 

B cd37 NHL Find trials
>
 
15 Reports

 
Bexxar ®
anti-CD20 + iodine 131
DISCONTINUED by GSK
 

B cd20 NHL Find trials
>
 
69 Reports

 
Zevalin ®
anti-CD20 + Yttrium 90

(Ibritumomab tiuxetan)
 

B cd20 NHL Find trials
>
 
113 Reports

 
epratuzumab tetraxetan
anti-CD22 with fractionated Yttrium 90 
 

B cd22 - Find trials
>
 
71 Reports

Immune-mediated

Immune mediated therapy assists in helping the immune system to attack the tumor.

See also antibody agents, and radioimmunotherapy

 
Agent or class

  Target  

Find Trials

Count Reports

 
Anti-PD-1 antibody

pidilizumab (CT-011)

OR

BMS-936558 (
nivolumab)
 
 
(Immune checkpoint blockade)

B PD-1 (P7) Initial
count: 195


 
>
Find trials

>
Total
272
Reports

 
ipilimumab

anti-CTL-A (MXD-010)

(Immune checkpoint blockade)

B CTL-A
t-reg
-

Find trials
>
 

15 Reports


immunocytokine therapy

Two immune components – antibodies and cytokines

- - - Find trials
>
 
6 Reports


Revlimid ® / Lenalidomide / CC 5013

(Immune modulating / cereblon)

- unknown MDS / myeloma Find trials
>
 
95 Reports

Lenalidomide AND Rituxan

- unknown + cd20 New combination Find trials
 >
 
4 Reports

Pomalidomide 

(Immune modulating)

- unknown NEW Find trials
>
 
5 Reports

T-cell therapy

(adoptive immunotherapy)

B or T - - Find trials
 >
 
14  

cd19 CAR T-cell therapy

(CAR - chimeric antigen receptor)

(
adoptive immunotherapy)

B cd19 Initial count: 148 >  (updated)

> (New count)
Find trials 

(revised query 10/11)

 



184
 
Reports

About by PAL

Vaccine (idiotype) therapy

B tumor antigen - Find trials
 >
32 Reports

Cytotoxic Agents

Damage the DNA of rapidly dividing cells, triggering apoptosis (programmed cell death)

 

Agent

  Target  

Find Trials

Count Reports


Treanda ®

(Bendamustine)
 
 

B or T DNA NHL/CLL Find trials
>
78 Reports


Bendamustine
phase 3 trials

B or T DNA NHL/CLL Phase 3 trials
>
25 Reports


Folotyn ® (Pralatrexate)

- DNA T-cell Find trials
>
6 Reports


Pixantrone
 

Request:  Open Studies >
  

B DNA - Find trials

>
 
7

Reports


Targeted Agents

    


Epigenetic Agents

Agents that modify gene expression (by methylation or acetylation of histones and other elements) can reprogram how tumor cells behave: grow, die, or differentiate by activating or turning on genes.


DNA hypo/hyper-methylation

can reactivate tumor suppressor genes by altering methylation

Hypermethylation-associated silencing of tumor suppressor genes has been shown to occur in lymphoid/hematopoietic malignancies, disrupting many cellular pathways.1-3 Unlike genetic alterations in cancer, hypermethylation changes are potentially reversible by pharmacologic inhibition of DNA methylation.4 The cytidine analogs 5-aza-2′-deoxycytidine and 5-azacytidine are capable of reactivating tumor suppressor genes that were silenced by hypermethylation.4

Agent

  Target  

Find Trials

Count Reports


Vidaza ®
 
(5-Azacytidine)

B DNA hypo-methylation initial
count: 19
>

 Find trials
>
20 Reports

HDAC inhibition

interferes with the function of histone deacetylase - modifying gene expression    About by PAL

 

Agent

  Target  

Find Trials

Count Reports


Abexinostat (PCI-24781)

  HDAC   Find trials
>
25 Reports

Belinostat (PXD101)
T or B HDAC   Find trials
>
32 Reports

Panobinostat (LBH589)
T or B HDAC   Find trials
>
54 Reports

Romidepsin ® (Depsipeptide)
T or B HDAC Approved for T-cell lymphoma Find trials
> 
21 Reports

Valproic acid
T or B HDAC AML / MDS Find trials
 >
78 Reports
Zolinza ® (Vorinostat)
T or B HDAC Approved for T-cell lymphoma Find trials
>
87 Reports


targeting BCL-2
(apoptosis activation)

Binds to BCL-2 pathway involved in the blocking of apoptosis (programmed cell death)

 


Agent

- Target -

Find Trials

Count Reports

ABT-199 

B bcl-2
pathway
- 

Find trials

54  
Reports

>

ASCO report
 

Obatoclax mesylate / GX15-070)
B bcl-2
pathway
-

-

Find trials 51  
Reports

>
 

mTOR

Binds mTOR pathway that promotes survival and cell growth

 

 
Agent

  Target -

Find Trials

Count Reports

CC-223

dual mTOR inhibitor (oral)
B mTOR - Find trials 21  
Reports

>
 

Everolimus / RAD001 (oral)
B mTOR -- Find trials 52  
Reports

>

Leukemia report
   


Temsirolimus / CCI-779 (IV)
B mTOR -- Find trials
 
38  
Reports

>
 

 
Kinase inhibitors

Inhibit pathways that are overactive in cancer cells

See for explanation:  Agents that target disease pathways
 
     B-cell Receptor pathway
 
 
 
Target
 
       

AVL-292
B BTK - Find trials 98
 
Reports

>
 
  
 
Idelalisib / GS-1101
/ CAL101
B PI3k delta - Find trials
 
529  
 
Reports

>

Lymphomahub 2013

 


Ibrutinib
(PCI-32765) 
 
B BTK - Find trials 629  
 
Reports

>

About by PAL
 


Ibrutinib
 (CLL studies)
 

B - - Find trials
 
75 >

Ibrutinib
(lymphoma studies)

B -- - Find trials
 
New >

IPI-145

B or T  
(PI3K)-delta and PI3K-gamma
 
- Find trials 27
Reports

>
 

    Other kinase inhibitors
 
Target
-
Find Trials
Count
Reports


AEB071 (Sotrastaurin)

subtype
of DLBCL
 
 Protein Kinase C Inhibitor
 
- Find trials
 
8


Report

>
 


Alisertib (MLN8237)
  
T Aurora Kinase A - Find trials 23  
Reports

>
 
Alisertib  report: http://bit.ly/18sChgG
 


Other targeted agents

 
 
Lymphoma / CLL trials of new agents with search of literature for underlined agent
 
bullet
* Selective Inhibitor of Nuclear Export (SINE) KPT-330
Safety study in Patients With Advanced Hematological Cancer
http://1.usa.gov/1pPJNuo

* Background article in Haematologica. Jul 2013:
Selective inhibitors of nuclear export for the treatment of non-Hodgkin’s lymphomas
http://1.usa.gov/1lVKX7u
 
bullet
SAR 245409 is a potent oral pan-inhibitor of PI3K

     * List Results - ClinicalTrials.gov http://1.usa.gov/1hyV6Wi
bullet
copanilisib (BAY 80-6946), is an intravenously administered compound that has significant activity
against alpha and delta isoforms of PI3K; the delta isoform has a role in B-cell signaling, development

      * List results -  ClinicalTrials.gov http://1.usa.gov/1glACLs
bullet
PNT2258 DNAi molecule targets the noncoding, nontranscribed regulatory region of the Bcl2 gene.

       * List Results - ClinicalTrials.gov http://1.usa.gov/1nQQad1 
bullet
XmAb5574 / MOR00208 (optimized cd19 Mab)  Find trials

About study drug From morphosys.com: http://bit.ly/1kiAP8s
bullet
Ruxolitinib  (inhibitor of cytokine-signaling) - Find trials 

Related Citations for PubMed (Select 22869151) - PubMed - NCBI

Background on this drug for other indications: wikipedia.org
bullet
Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary
Mediastinal Large B-cell Lymphoma - Full Text View - ClinicalTrials.gov http://1.usa.gov/19YXLEf 
 
bullet
AZD6738 First Time in Patient Multiple Ascending Dose Study - http://1.usa.gov/19TnU1m
bullet
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma http://1.usa.gov/15MC83D
bullet
A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With
Solid Tumors or Lymphoma -   http://1.usa.gov/1d6jTxS
bullet

PF-05082566 As A Single Agent And In Combination With Rituximab  http://1.usa.gov/1b6LCby

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies http://bit.ly/1aXT0cB 

PF-05082566 is an anti-CD-137 agonist antibody that is designed to help the immune system
go after the lymphoma cells with Rituxan attached to them."
 

bullet

Acetylon Announces Preclinical Data of ACY-1215 for the Treatment of Lymphoma
Highlighted at 12th International Conference on Malignant Lymphoma (ICML) |
Business Wire
http://bit.ly/1hDNjBL 

HDACs regulate the activity of tumor-suppressor genes and oncogenes that play
crucial roles in tumorigenesis37 and therefore have been studied as therapeutic
targets in solid tumors and hematologic malignancies

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337713/

Rocilinostat (ACY-1215) is a selective HDAC6 inhibitor with IC50 of 5 nM. It is
>10-fold more selective for HDAC6 than HDAC1/2/3 (class I HDACs) with slight
activity against HDAC8, minimal activity against HDAC4/5/7/9/11, Sirtuin1, and
Sirtuin2.


Agent

  Target  

Find Trials

Count Reports

Crizotinib

  ALK   http://1.usa.gov/1khJYwL   http://1.usa.gov/1olUwxA
PD 0332991
  Cdk - Find trials
>
19 Reports

ISIS 481464 (AZD9150)

antisense oligonucleotide
inhibitor of STAT3

  STAT3   Find trial
>
NEW Report
YM155
B survivin kinase - Find trials
>
61 Reports
proteasome inhibitors

MLN970 / Bortezomib /
Velcade
® , Carfilzomib,
CEP 18770 
  proteasome inhibitors - Find trials
>
10 Reports
TL32711  
  inhibitors of apoptosis   Find trials
 >
8 Reports

Discontinued agents

 
 
Enzastaurin
B C-beta - Find trials
>
25 Reports
Navitoclax / ABT-263 >
 
Discontinued due to improvement in safety with ABT-199 above
B bcl-2
pathway
- http://bit.ly/5fcv13 99 Reports
             

See also Find Clinical Trials based on Type of Lymphoma and Clinical Circumstance

 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright © 2004,  All Rights Reserved.